We invite you to explore the recent article “Next Level Biopharmaceuticals” featured in the Business Focus Magazine’s latest issue. Business Focus Magazine interviewed Biovian’s CEO and co-founder Antti Nieminen about Biovian’s growth story and position …
We are delighted to tell you that Biovian will be participating in the Biotech Week Boston on September 18-21, 2023! You can meet our team at the concurrent BPI/Cell & Gene Therapy Manufacturing & Commercialization …
Biovian Oy, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, announces a major investment of over €50 million to expand its manufacturing facility in Turku, Finland. The new facility will cover an …
Biovian is gearing up to exhibit at the highly anticipated BIO International Convention in June 5-8, 2023. This premier global event will bring together pioneers, innovators, and thought leaders from around the world to explore …
Biovian will be exhibiting at the 26th Annual ASGCT Meeting held in Los Angeles, in May 16-20, 2023. Meet the Biovian representatives Magnus Gustafsson CBO, Eero Mustalahti Head of Business Development and Taru Värri Marketing …
According to the Merriam-Webster Dictionary, the English noun “solution” refers to: i) an action or process of solving a problem, ii) a bringing or coming to an end or into a state of discontinuity, iii) …
We are delighted to welcome Dr. Uwe Gottschalk to Biovian’s Board of Directors. “At Keensight, we are very pleased to welcome Uwe to the Board of Biovian” said Dr. Pierre Remy, Chairman of the Board. …
Biovian is looking forward to participating in the BIO International Convention on June 13th-16th in San Diego. #BIO2022 is back in person. Biovian representatives, CBO Magnus Gustafsson and Head of Business Development Eero Mustalahti are …
Viral contaminations are rare events in biopharmaceutical manufacturing, but regulatory agencies expect all biologics to undergo viral clearance testing to mitigate the risk of contamination [1, 2]. Therapies based on viral vectors have a small …
The article discusses the reasons behind the growing need for viral vectors and how Biovian, as a CDMO has taken actions to solve the manufacturing bottleneck. Antti Nieminen, CEO of Biovian: “The majority of Biovian’s customers …
